# Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

> **NCT02829008** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** low-dose-bevacizumab/pemetrexed
- **DRUG:** Treatment of physician's choice

## Key facts

- **NCT ID:** NCT02829008
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-04
- **Final completion:** 2020-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829008, "Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02829008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*